Xofluza® (baloxavir marboxil) – New indication, new formulation approval
November 23, 2020 - Genentech announced the FDA approval of Xofluza (baloxavir marboxil), for post-exposure prophylaxis of influenza in persons 12 years of age and older following contact with an individual who has influenza.
Download PDF
